Price
$126.78+55.48%1Y
1M-0.77%1Y+55.48%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Average6/10
Value40
Quality84
Momentum46
Growth36
P/E (TTM)33.4
Market Cap$281.24B
1Y Return+55.48%
5Y Return+83.99%
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $9.29B (-10.83%)
●Alliance Revenue Koselugo grew +265.91% YoY●Lagevrio -72.55% YoY
SegmentLatestQoQYoY
- Keytruda$4.60B-5.74%+6.75%
- Gardasil Gardasil9$485.0M-57.97%-9.51%
- Winrevair$477.0M+42.39%+77.99%
- Bridion$427.0M+8.93%+12.96%
- Pro Quad MMRIIVarivax$409.0M-26.17%-3.31%
- Companion Animal$308.0M+5.84%0.00%
- Januvia$252.0M-2.33%-26.74%
- Livestock$211.0M-0.94%+8.76%
- Lenvima$176.0M-0.56%-5.38%
- Other Pharmaceutical$166.0M-30.54%-26.87%
- Rotateq$165.0M+17.02%+0.61%
- Alliance Revenue Koselugo$161.0M-24.77%+265.91%
- Welireg$152.0M-5.59%+23.58%
- Alliancerevenue Lynparza$149.0M-19.02%+2.76%
- Prevymis$135.0M+5.47%+32.35%
- Ohtuvayre$131.0M--
- Alliance Revenue Reblozyl$128.0M+15.32%+26.73%
- Vaxneuvance$123.0M-8.21%-11.51%
- Capvaxive$118.0M-50.42%+11.32%
- Alliance Revenue Adempas Verquvo$109.0M+5.83%+12.37%
- Keytruda Qlex$106.0M--
- Adempas$78.0M-4.88%+14.71%
- Janumet$68.0M-12.82%+4.62%
- Zerbaxa$52.0M+6.12%+23.81%
- Isentress Isentress HD$35.0M-20.45%-31.37%
- Lagevrio$28.0M-79.71%-72.55%
- Dificid$24.0M-20.00%-66.67%
- Delstrigo$10.0M-23.08%-33.33%
- Verquvo$9.0M-25.00%0.00%
- Belsomra---
- Cancidas---
- Companion Animals---
- Invanz---
- Noxafil---
- Pifeltro---
- Pneumovax23---
- Primaxin---
- Remicade---
- Simponi---
- Vaqta---